In this chapter, we describe the changing landscape of the EU pharmaceutical legislation concerning regulation and evidence requirements for marketing authorisation. First, we describe the legal requirements for marketing authorisation and the development of EU pharmaceutical legislation and the concept of risk-benefit balance. Second, we describe special types of authorisation, such as conditional approval and approval under exceptional circumstances, and special provisions such as incentives for orphan medicinal products and paediatric investigational plans. Lastly, we describe the available methodological guidelines focussing on choice of endpoints.
CITATION STYLE
Walter, E. (2019). Regulatory and Economic Aspects in Oncology. Recent Results in Cancer Research (Vol. 213, pp. 169–187). Retrieved from http://www.springer.com/series/392
Mendeley helps you to discover research relevant for your work.